R&D investment dominates interim results
​Verona is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced by existing drugs. Important Phase II trial results are due to be announced during October 2015. Despite positive share price appreciation during 2015 there remains a mis-match between the current EV (£44m) and a potential inflection point on positive Phase II data, especially when considering that median valuations for Phase II respiratory assets have headline valuations of $285m (£190m), or 19p per share.Â
Verona Pharam a clinical stage biopharmaceutical company focused on developing and commercialising therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Co.'s product candidate, RPL554, is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Co. is developing RPL554 for the treatment of patients with chronic obstructive pulmonary disease, as well as for the treatment of cystic fibrosis, a fatal inherited disease. Co. may also explore, alone or with a collaborator, the development of RPL554 to treat asthma and other respiratory diseases.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.